<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913389</url>
  </required_header>
  <id_info>
    <org_study_id>01-2021-KEB</org_study_id>
    <nct_id>NCT04913389</nct_id>
  </id_info>
  <brief_title>Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD</brief_title>
  <official_title>Novel Approach to Prevention of Altitude-related Illness in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Cardiology and Internal Medicine, Kyrgyz Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, placebo-controlled double-blind trial is to evaluate efficacy&#xD;
      of acetazolamide in preventing overt altitude-related adverse health effects (ARAHE) in&#xD;
      lowlanders with chronic obstructive pulmonary disease (COPD) developing early signs of&#xD;
      altitude-illness during altitude travel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized placebo-controlled, double-blind, parallel-design trial will evaluate&#xD;
      effectiveness of acetazolamide in reducing the incidence of predefined altitude-related&#xD;
      adverse health effects in lowlanders with chronic obstructive pulmonary disease (COPD)&#xD;
      travelling to high altitude and developping early symptoms and/or signs of impending&#xD;
      altitude-illness. Qualifying participants will be randomized 1:1 to acetazolamide or placebo&#xD;
      treatment during their further stay of 2 days at 3'100 m.&#xD;
&#xD;
      An interim-analysis will be performed after the first year of the study or when 38&#xD;
      participants are randomized, whichever comes first. Symmetric stopping boundaries at P&lt;0.001&#xD;
      will be applied (Peto approach).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, placebo-controlled, double-blind</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>An independent pharmacist will prepare identically looking active and placebo capsules labelled with secret codes. Codes will be concealed to investigators and patients until completion of data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of altitude-related adverse health effects</measure>
    <time_frame>Day 1 to 3 at 3'100m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in the incidence of altitude-related adverse health effects defined as:&#xD;
Moderate to severe acute mountain sickness (Lake Louise score &gt;4 including headache and/or Acute Mountain Sickness cerebral score ≥0.7)&#xD;
Severe hypoxemia (SpO2 at rest &lt;80% for &gt;30 min; or SpO2 &lt;75% for &gt;15 min; or exercise oxygen desaturation SpO2 &lt;75% for &gt;1 min accompanied by symptoms or signs of hypoxemia)&#xD;
Symptomatic cardiovascular disease (arterial blood pressure systolic &gt;200 mmHg, diastolic &gt;120 mmHg, chest pain with ECG signs of cardiac ischemia)&#xD;
New onset neurologic impairment&#xD;
Other intercurrent illness requiring medical treatment&#xD;
Any discomfort leading to the wish of a patient to return to low altitude or withdraw from the study by the independent physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of the individual components of altitude-related adverse health effects</measure>
    <time_frame>Day 1 to 3 at 3'100m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in the incidence and severity of components of altitude-related adverse health effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial blood gases</measure>
    <time_frame>Day 2 at 3'100 m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in arterial blood gases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Day 2 at 3'100 m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in forced expiratory volume in one second (FEV1) measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC)</measure>
    <time_frame>Day 2 at 3'100 m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in forced vital capacity (FVC) measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug side effects</measure>
    <time_frame>Day 1 to 3 at 3'100m</time_frame>
    <description>Difference between participants receiving acetazolamide and placebo in the incidence of drug side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Altitude Sickness</condition>
  <condition>Altitude Hypoxia</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetazolamide (oral capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (oral capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Acetazolamide (oral capsules @125 mg), starting dose 3 capsules (375 mg), subsequent doses 1 capsule (125 mg) in the morning, 2 capsules (250 mg) in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Acetazolamide, oral capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (oral capsules, identically looking as active drug), starting dose 3 capsules, subsequent doses 1 capsule in the morning, 2 capsules in the evening, administered in qualifying participants, during the stay at 3100 m.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, oral capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Men and women, age 35-75 y, living at low altitude (&lt;800 m).&#xD;
&#xD;
          -  COPD diagnosed according to the Global Initiative for Obstructive Lung Disease (GOLD)&#xD;
             guidelines, forced expiratory volume in one second 40-80% predicted, pulse oximetry&#xD;
             ≥92%, PaCO2 &lt;6 kilopascal, breathing ambient air at 760 m.&#xD;
&#xD;
          -  One of the following early signs and/or symptoms of impending altitude-illness&#xD;
             identified by self-monitoring during ascent to or stay at 3100 m:&#xD;
&#xD;
               -  Pulse oximetry SpO2≤84%&#xD;
&#xD;
               -  Headache or nausea/vomiting or fatigue/weakness or dizziness/light-headedness of&#xD;
                  at least moderate intensity&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  COPD exacerbation, very severe COPD with hypoxemia or hypercapnia at 760 m (see&#xD;
             above).&#xD;
&#xD;
          -  Other lung disease, relevant comorbidities (such as uncontrolled cardiovascular&#xD;
             disease, i.e., unstable arterial hypertension, coronary artery disease; previous&#xD;
             stroke; obesity (body mass index &gt;35 kg/m2); internal, neurologic, rheumatologic or&#xD;
             psychiatric disease; current heavy smoking (&gt;20 cigarettes per day).&#xD;
&#xD;
          -  Renal failure and/or allergy to sulfonamides.&#xD;
&#xD;
          -  Patients who do not have early signs and/or signs of impending altitude-illness by&#xD;
             self-monitoring (as defined above) at 3'100m will not be included.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Zürich, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talant M Sooronbaev</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Furian</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad E Bloch</last_name>
    <phone>+41442553828</phone>
    <email>konrad.bloch@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Furian</last_name>
    <phone>+4144794037586</phone>
    <email>michael.furian@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center of Cardiology and Internal Medicine</name>
      <address>
        <city>Bishkek</city>
        <zip>720040</zip>
        <country>Kyrgyzstan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talant M Sooronbaev, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Kyrgyzstan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Mountain sickness</keyword>
  <keyword>Hypoxemia</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

